Viridian Therapeutics Inc
VRDN
Market Cap$933.72M
Close$
$1.79
86.7% downside
Current Fair Value
86.7% downsideOvervalued by 86.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $933.72 Million |
|---|---|
| Enterprise Value | $340.86 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-4.41 |
| Beta | 1.36 |
| Outstanding Shares | 63,822,468 |
| Avg 30 Day Volume | 852,631 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -4.28 |
|---|---|
| PEG | 14.88 |
| Price to Sales | - |
| Price to Book Ratio | 1.49 |
| Enterprise Value to Revenue | 1183.55 |
| Enterprise Value to EBIT | -1.43 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
ESG Score
No data
About Viridian Therapeutics Inc
27 employees
CEO: William Marshall Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a clinical-stage anti-IGF-1R mono...